Page 98 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

Chapter 5
Table 1. Baseline demographic and clinical characteristics
Gender, female Age (years)
Monthly Headache days (MHD) Monthly Migraine days (MMD) Duration of migraine (years) HIT 6 score a
Treatment within drug trial Botulinum toxin A
Placebo
Monthly days with acute headache medication
Type of overuse
Triptans
Simple analgesics b
Combination of acute medication c
Prophylaxis d
Current use
History of use e
Number of used prophylactics
Anxiety, % present (HADS-A ≥ 8) Anxiety, mean HADS-A score
Depression, % present (HADS-D ≥ 8) Depression, mean HADS-D score
Maximal intervention (n=90)
67 (74.4%) 45.3 ± 10.9
21.3 ± 4.6 15.3 ± 5.5 27.3 ± 13.0 65.3 ± 4.4
45 (50%) 45 (50%)
16.7 ± 5.6
18 (20.0%) 2 (2.2%) 70 (77.8%)
29 (32.2%) 84 (93.3%) 2.5 ± 1.8
31 (34.4%) 6.4 ± 4.0
35 (38.9%) 6.5 ± 4.4
Minimal intervention (n=89)
69 (77.5%) 45.1 ± 10.7
21.5 ± 4.9 14.9 ± 5.5 27.9 ± 12.9 64.7 ± 4.1
45 (50.6%) 44 (49.4%)
16.2 ± 5.6
15 (16.9%) 5 (5.6%) 69 (77.5%)
36 (40.4%) 79 (88.8%) 2.2 ± 1.8
24 (27.0%) 6.0 ± 3.7
31 (34.8%) 6.3 ± 3.9
96
Values are absolute numbers with corresponding %, or means ± SD
a N maximal intervention = 85, N minimal intervention= 89; b Simple analgesics: paracetamol, NSAID’s; c Combined medication: combination of triptan, simple analgesics or combination drugs such as paracetamol and caffeine;
d Commonly used prophylaxis for migraine; e History of use: current or past use of at least one type of prophylaxis.